Arora, Gunjan, Shrivastava, Ruchi, Kumar, Prashant et al. (6 more authors) (2021) Recent advances made in the synthesis of small drug molecules for clinical applications:An insight. Current Research in Green and Sustainable Chemistry. 100097. ISSN 2666-0865
Abstract
Over decades dependency of humans on the drugs has become indispensable and irreplaceable. Thus, each year many new drugs are licensed. Nonetheless, drugs undergo rigorous testing and analysis to be available globally in economic price for the suitability of patients with different age and physiological conditions. The testing of drugs include phase I clinical trial using small group of 20–100 healthy volunteers for safety, pharmacology and efficacy; phase II clinical trial using 100–500 volunteer patients to optimize effective dose, dose interval, safety analysis and mode of delivery such as oral or intravenous; phase III clinical trial using 1000–5000 in a larger population of patients globally at different international places to collect sufficient safety and efficacy data for patenting and licencing. Moreover, thousands of drugs fail to achieve these objectives. Therefore, this mini-review intends to critically examine and assimilate the clinical applications of selected complex repurposed small drug molecules which are in different phase of trials for treating viral infection including complications due to COVID-19: (a) Remdesivir, (b) Galidesivir, (c) Favipiravir, (d) Baricitinib, and (e) Baloxavir.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | Funding Information: Fund Researcher Links workshop grant, ID 2018-RLWK10-10480. The grant was funded by the UK Department for Business, Energy and Industrial Strategy and the Royal Society of Chemistry and delivered by the British Council . Funding Information: The Authors would like to acknowledge that this work is the direct output of a Newton Fund Researcher Links Workshop grant, ID 2018-RLWK10-10480, between the United Kingdom and India, which allowing researchers to collaborate. The grant is funded by the UK Department for Business, Energy and Industrial Strategy and The Royal Society of Chemistry and delivered by the British Council . For further information, please visit www.newtonfund.ac.uk . Publisher Copyright: © 2021 The Author(s) |
Keywords: | Baloxavir,Baricitinib,Clinical applications,COVID-19,Drug repurposing,Favipiravir,Galidesivir,Remdesivir,Small drug molecules |
Dates: |
|
Institution: | The University of York |
Academic Units: | The University of York > Faculty of Sciences (York) > Chemistry (York) |
Depositing User: | Pure (York) |
Date Deposited: | 15 Oct 2021 12:00 |
Last Modified: | 16 Oct 2024 17:55 |
Published Version: | https://doi.org/10.1016/j.crgsc.2021.100097 |
Status: | Published |
Refereed: | Yes |
Identification Number: | 10.1016/j.crgsc.2021.100097 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:179278 |
Download
Filename: 1_s2.0_S2666086521000448_main.pdf
Description: 1-s2.0-S2666086521000448-main
Licence: CC-BY-NC-ND 2.5